duloxetine has been researched along with milnacipran in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
| Chen, C; Dyck, B; Fleck, BA; Foster, AC; Grey, J; Jovic, F; Mesleh, M; Phan, K; Tamiya, J; Vickers, T; Zhang, M | 1 |
| Bradbury, MJ; Chen, C; Dyck, B; Fleck, BA; Foster, AC; Grey, J; Johns, M; Jovic, F; Li, B; Madan, A; O'Brien, J; Pick, RR; Saunders, J; Tamiya, J; Tran, JA; Vickers, T; Wen, J; Zhang, M | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chang, R; Church, TJ; Jaw-Tsai, S; Martin, WJ; Saito, DR; Smith, JA; Stangeland, EL; Van Dyke, PM; Van Orden, LJ | 1 |
| Badescu, VO; de Frutos, O; de la Puente, ML; Ding, C; Dreyfus, N; Filla, SA; Fynboe, K; Gernert, DL; Heinz, BA; Hemrick-Luecke, SK; Iyengar, S; Johansson, AM; Johnson, KW; Johnson, MP; Joshi, E; López, P; Love, PL; Martin, LJ; Masquelin, T; McCoy, MJ; Mendiola, J; Morrow, D; Muhlhauser, M; Myers, JK; Pascual, G; Perun, TJ; Pfeifer, LA; Phebus, LA; Richards, SJ; Rincón, JA; Seest, EP; Shah, J; Shaojuan, J; Simmons, RM; Stephenson, GA; Thomas, CE; Thompson, LK; Tromiczak, EG; Walter, MW; Weber, WW; Zarrinmayeh, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for duloxetine and milnacipran
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for duloxetine and milnacipran
| Article | Year |
|---|---|
Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.
Topics: Acetamides; Alkylation; Amides; Cyclopropanes; Indoles; Milnacipran; Models, Molecular; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Stereoisomerism; Structure-Activity Relationship; Vesicular Monoamine Transport Proteins | 2008 |
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
Topics: Administration, Oral; Animals; Biological Availability; Caco-2 Cells; Crystallography, X-Ray; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Microsomes, Liver; Milnacipran; Models, Molecular; Molecular Structure; Molecular Weight; Neuralgia; Norepinephrine Plasma Membrane Transport Proteins; Pain Measurement; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Spinal Nerves; Stereoisomerism; Structure-Activity Relationship | 2008 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
Topics: Animals; Crystallography, X-Ray; Disease Models, Animal; Humans; Nerve Tissue Proteins; Neurotransmitter Uptake Inhibitors; Norepinephrine; Pain; Pyrrolidines; Rats; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship | 2013 |
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
Topics: | 2013 |